title: [Lymph node dissection in lung cancer].
abstract: The standard surgical treatment for stage I, II, and IIIa non-small cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection. In our series of 214 patients with N2 disease the 5-year survival rate was 23%. Systematic mediastinal lymph node dissection provides further prognostic information on the N factor. Among NSCLC patients with a pathological diagnosis of N2, there are significant differences in the 5-year survival rate based the 3 factors of clinical N factor, N1 station metastasis, and N2 station metastasis.
authors: Department of Chest Surgery, Tokyo Medical University, Kasumigaura Hospital, Ibaraki, Japan.
authors: M
authors: M
authors: Saito
authors: T
authors: T
authors: Miura
authors: K
authors: K
authors: Furukawa
authors: H
authors: H
authors: Kato
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008197:Lymph Node Excision / Q000379:methods*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged